RXRX — Recursion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.70bn
- $74.68m
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million
Recursion Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber
U.S. STOCKS ON THE MOVE-AMD, Apollo, Deckers Outdoor
Recursion falls after quarterly revenue miss
Recursion Pharmaceuticals misses Q1 operating revenue estimates, net loss narrows
Brief: Recursion Pharmaceuticals Inc - Appoints Vicki Goodman As Chief Medical Officer Effective April 6, 2026
Brief: Pacbio Announces The Appointment Of Chris Gibson To The Board Of Directors
Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments
Applied Digital, WeRide shares fall after Nvidia dissolves stake
Brief: Novo Holdings Dissolves Share Stake In Recursion Pharmaceuticals
Brief: Nvidia Reports Share Stake In Intel, Nokia; Dissolves In ARM, Weride
Brief: Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules